Pizzi C, Mancini S, Angeloni L, Fontana F, Manzoli L, Costa G M
Department of Internal Medicine, Aging and Nephrological Diseases, University of Bologna, Bologna, Italy.
Clin Pharmacol Ther. 2009 Nov;86(5):527-32. doi: 10.1038/clpt.2009.121. Epub 2009 Jul 29.
We investigated the effect of sertraline on inflammation and endothelial function in patients with coronary heart disease (CHD) and symptoms of depression. One hundred patients with CHD and depression were randomized in a double-blind fashion to receive sertraline or a placebo. We measured symptoms of depression (Beck Depression Inventory (BDI) score), levels of inflammatory markers (C-reactive protein (CRP) and interleukin-6 (IL-6)), and flow-dependent endothelium-mediated dilation (FMD) before and after 20 weeks of treatment. Sertraline treatment significantly reduced the BDI score as compared with both baseline and placebo. Levels of CRP and IL-6 also decreased after 20 weeks of sertraline treatment, whereas they did not significantly change in the placebo group. There was a significant improvement in FMD in patients on sertraline treatment, whereas there was no change in FMD in the placebo group. Sertraline improves endothelial function and reduces inflammatory markers in patients with CHD and symptoms of depression.
我们研究了舍曲林对冠心病（CHD）合并抑郁症状患者炎症和内皮功能的影响。100例冠心病合并抑郁症患者以双盲方式随机分组，分别接受舍曲林或安慰剂治疗。我们在治疗20周前后测量了抑郁症状（贝克抑郁量表（BDI）评分）、炎症标志物水平（C反应蛋白（CRP）和白细胞介素-6（IL-6））以及血流依赖性内皮介导的血管舒张功能（FMD）。与基线水平和安慰剂相比，舍曲林治疗显著降低了BDI评分。舍曲林治疗20周后，CRP和IL-6水平也有所下降，而安慰剂组则无显著变化。接受舍曲林治疗的患者FMD有显著改善，而安慰剂组FMD无变化。舍曲林可改善冠心病合并抑郁症状患者的内皮功能并降低炎症标志物水平。
